Abstract
Importance Phase 3 randomized controlled trials (RCTs) of mRNA COVID-19 vaccines in children and adolescents showed efficacy in preventing COVID-19 infections. Vaccines may have non-specific effects; this is not assessed within the current regulatory framework.
Objective Conduct a systematic review and meta-analysis of the phase 3 trials to assess overall and non-specific health effects of the mRNA COVID-19 vaccines in children.
Data Sources PubMed, Embase, Clinical Trials, Web of Science, and regulatory websites were searched for RCTs of mRNA vaccines. The latest trial data was included.
Study Selection All RCTs conducted with mRNA vaccines BNT162b2 and mRNA-1237 in children and adolescents below 18 years of age, with placebo, adjuvant, or other vaccines as controls. Two authors independently screened 1199 studies, six were included in the analysis.
Data Extraction and Synthesis Data on serious adverse events (SAEs) and severe adverse events (AEs) as well as organ-specific diseases was extracted following the PRISMA reporting guideline, with a focus on non-specific infectious events. Risk Ratios (RRs) comparing vaccine and placebo cohorts were calculated separately for each vaccine and combined in Mantel-Haenszel estimates.
Main Outcomes and Measures The primary outcome was SAEs, overall and infectious. Secondary outcomes were severe AEs and lower respiratory tract infection (LRTI) including RSV.
Results The analyses included 25,549 individuals (17,538 mRNA vaccine recipients and 8,011 placebo recipients). The risk of SAEs was similar for vaccine and placebo recipients. Both mRNA vaccines were associated with increased risk of severe AEs in older children. In a combined analysis, the RR was 3.77 (1.56-9.13[0.4% vs 0.1% in vaccine vs placebo recipients]) in above 5 year-olds, and 0.82 (0.53-1.29)[0.8% vs 0.9%])in younger children (p=0.003 for same effect in older and younger children). In the younger children, mRNA vaccines were associated with higher risk of LRTI (RR=3.03 (1.29-7.09)[0.6% vs 0.2%]).
Conclusions and Relevance mRNA vaccines did not increase the risk of SAEs but were associated with an increased risk of severe AEs in older children, and an increased risk of LRTI in the young. Further research into the overall and non-specific health effects of mRNA vaccines is warranted.
Question What is the overall health effect of mRNA COVID-19 vaccines in children?
Findings In this systematic review and meta-analysis of phase 3 trials, mRNA vaccine vs. placebo was not associated with increased risk of serious adverse events. The mRNA vaccines were associated with higher risk of severe adverse events in children aged 5 years and older. In children younger than 5 years, mRNA vaccines were associated with a 3-fold higher risk of lower respiratory tract infections.
Meaning The results suggest that mRNA vaccines are associated with increased risk of severe adverse events and increased risk of LRTI. Given the low risk of severe COVID-19 infection in children, it is not clear that the benefits of COVID-19 vaccines in children outweigh the harms.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The study was funded by a grant from the Bluebell Foundation
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Minor cosmetic changes.
Data Availability
All data produced in the present work are contained in the manuscript
